NasdaqGS - Delayed Quote USD

Illumina, Inc. (ILMN)

116.69 -1.60 (-1.35%)
At close: April 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Jacob Thaysen Ph.D. CEO & Director 796.63k -- 1975
Ms. Carissa L. Rollins Chief Information Officer 693.52k -- 1970
Mr. Charles E. Dadswell Esq. Senior VP & General Counsel 1.03M -- 1959
Stephanie Campos President -- -- --
Mr. Ankur Dhingra Chief Financial Officer -- -- 1976
Mr. Kevin Carl Pegels Chief of Global Operations -- -- 1968
Mr. Scott Ericksen VP & Chief Accounting Officer -- -- 1973
Dr. Steven Barnard Ph.D. Chief Technology Officer -- -- --
Ms. Sallilyn Schwartz Vice President of Investor Relations -- -- --
Mr. Jakob Wedel Chief Strategy & Corporate Development Officer and CEO Chief of Staff -- -- --

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500 https://www.illumina.com
Sector: 
Healthcare
Full Time Employees: 
10,590

Description

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Illumina, Inc. Earnings Call

Related Tickers

EXAS Exact Sciences Corporation
63.48
+0.41%
 
GH Guardant Health, Inc.
16.67
+1.71%
 
TMO Thermo Fisher Scientific Inc.
541.52
-1.05%
 
TWST Twist Bioscience Corporation
28.36
-0.74%
 
A Agilent Technologies, Inc.
132.44
-1.57%
 
IDXX IDEXX Laboratories, Inc.
477.79
-0.09%
 
DHR Danaher Corporation
236.36
-1.27%
 
MTD Mettler-Toledo International Inc.
1,192.56
-0.46%
 
CRL Charles River Laboratories International, Inc.
227.55
-1.10%
 
IQV IQVIA Holdings Inc.
227.17
-0.04%